The use of an urticaria control test for the evaluation of omalizumab treatment response in patients diagnosed with chronic urticaria
Journal Title: Turkderm-Turkish Archives of Dermatology and Venereology - Year 2020, Vol 54, Issue 4
Abstract
Background and Design: Urticaria is a very common skin disease which is characterized by itchy, erythematous and edematous plaques. Angioedema can also be seen in half of the cases in addition to skin findings. In most cases of chronic urticaria, the underlying factor is not known. Omalizumab, a recombinant human monoclonal immunoglobulin G (IgG) antibody against IgE, is a safe treatment option in chronic urticaria cases which are resistant to treatment with antihistamines. This study aimed to evaluate the treatment responses of chronic urticaria patients taking omalizumab treatment with an urticaria control test (UCT). Materials and Methods: One hundred fifty-four patients diagnosed with chronic urticaria taking omalizumab treatment attended our evaluation between January 1, 2017 and December 31, 2018. These patients were evaluated with an UCT every four weeks. Sixty-six patients who were evaluated with an UCT during the course of the following 12 weeks were statistically analyzed. Thirty-nine of the patients received a treatment shorter than 12 months (the first group), and the remaining 27 patients received treatment for longer than 12 months (the second group). The patients were analyzed according to the duration of their treatment. Results: The first, second, and third average UCT scores of the 3 sequential applications for the first group were 9.16; 11.57; and 12.73; respectively. There was a statistically significant difference in the UCT scores between the 3 successive applications in the first group (p<0.05). On the other hand, the first, second, and third average UCT scores of the 3 sequential applications for the the second group were 11.20; 11.40; and 12.36 respectively. There was statistically significant difference in the UCT scores between the 3 successive applications for the second group. Conclusion: The effectiveness of omalizumab treatment in chronic urticaria patients with an UCT was investigated in this study. Omalizumab proved to be an effective treatment option in chronic urticaria patients.
Authors and Affiliations
Burhan Engin, Sera Nur Yücesoy, Özge Aşkın, Zekayi Kutlubay, Server Serdaroğlu
Keywords
Related Articles
- EP ID EP691625
- DOI 10.4274/turkderm.galenos.2020.06887
- Views 92
- Downloads 0
Acute generalized exanthematous pustulosis caused by a probable spider bite: A case report and review of the literature
Acute generalized exanthematous pustulosis (AGEP) is a toxic cutaneous reaction pattern that is mostly caused by drug intake and rarely associated with spider bites. We report a case of a female patient, 47 years old, wi...
Recommendations on the use of systemic treatments for urticaria and atopic dermatitis during the COVID-19 pandemic: Statement of Dermatoallergy Working Group of the Turkish Society of Dermatology
No summary
Information about sun exposure, protection, awareness and behavioural patterns of medical students in Kolar
Background and Design: The harmful ultraviolet radiation of sunlight can damage skin cells and affect the skin’s normal appearance. The short term effects associated with sun exposure include acute skin damage associated...
Complex aphthosis-like pemphigus vulgaris during pregnancy
No summary
A challenging diagnosis on dermoscopy: Lichen Planus Pigmentosus
No summary